Gilead Sciences Inc (GILD)

73.34
NASDAQ : Health Care
Prev Close 73.34
Day Low/High 0.00 / 0.00
52 Wk Low/High 63.76 / 82.10
Avg Volume 8.99M
Exchange NASDAQ
Shares Outstanding 1.31B
Market Cap 94.81B
EPS 10.10
P/E Ratio 7.88
Div & Yield 2.08 (2.90%)

Latest News

Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring

Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring

GlaxoSmithKline could be among the suitors for United Therapeutics, the Evening Standard reported.

Here's Why I'm Valuing Value Over Growth

Here's Why I'm Valuing Value Over Growth

Multiples have become quite rich and dysfunction in Washington could end up biting the markets.

European Commission Grants Marketing Authorization For Gilead's Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) For The Treatment Of All Genotypes Of Chronic Hepatitis C

European Commission Grants Marketing Authorization For Gilead's Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) For The Treatment Of All Genotypes Of Chronic Hepatitis C

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission has granted marketing authorization for Vosevi ® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg), as a once-daily single tablet...

Closing Our Gilead Sciences Position

Being able to tuck away gains on a trading day like this is a win.

Nasdaq Tumbles as Tech Takes a Turn Lower

Nasdaq Tumbles as Tech Takes a Turn Lower

The Nasdaq tumbles and the S&P 500 slides. The Dow rises slightly.

Wall Street Trades at Records as Facebook Rallies

Wall Street Trades at Records as Facebook Rallies

Stocks are higher.

Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers

Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers

Alexion Pharmaceuticals, United Therapeutics and Gilead Sciences were among the biotech stock movers in premarket trading on July 27.

Stock Futures Power Higher on Earnings Beat From Facebook

Stock Futures Power Higher on Earnings Beat From Facebook

Stock futures are higher.

Gilead Sciences Announces Third Quarter 2017 Dividend

Gilead Sciences Announces Third Quarter 2017 Dividend

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

Gilead Sciences Announces Second Quarter 2017 Financial Results

Gilead Sciences Announces Second Quarter 2017 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2017.

Another Day - Another Busy Slate of Earnings

Another Day - Another Busy Slate of Earnings

Ford Motor Co. leads a list of notable earnings reports being released throughout the day on Wednesday

Ford and the Fed - 5 Things You Must Know Before the Market Opens Wednesday

Ford and the Fed - 5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures are marginally higher on Wednesday ahead of an announcement from the Federal Reserve on interest rates.

Gilead Announces Phase 3 Results For Investigational Fixed-Dose Combination Of Bictegravir, Emtricitabine And Tenofovir Alafenamide For Treatment Of HIV

Gilead Announces Phase 3 Results For Investigational Fixed-Dose Combination Of Bictegravir, Emtricitabine And Tenofovir Alafenamide For Treatment Of HIV

Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48-week results from two Phase 3 studies (Studies 1489 and 1490) evaluating the efficacy and safety of a fixed-dose combination of bictegravir (50 mg) (BIC), a...

The Worm Has Turned in Biotech's Favor

The Worm Has Turned in Biotech's Favor

But this needs to heat up again for the sector to rally in a big way.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

The Worm Has Turned in Biotech's Favor

The Worm Has Turned in Biotech's Favor

However, it will take acquisition activity to heat up again for the sector to rally in a big way.

Stocks Are Guilty by Association: Cramer's 'Mad Money' Recap (Thursday 7/20/17)

Stocks Are Guilty by Association: Cramer's 'Mad Money' Recap (Thursday 7/20/17)

Jim Cramer says these market rotations are crushing good stocks that don't deserve it.

Try This Bullish Diagonal Spread on Gilead Sciences

We want to take advantage of the skew on the August and September calls and support our bullish thesis.

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

European Medicines Agency Validates Gilead's Marketing Application For Fixed-Dose Combination Of Bictegravir, Emtricitabine And Tenofovir Alafenamide For Treatment Of HIV

European Medicines Agency Validates Gilead's Marketing Application For Fixed-Dose Combination Of Bictegravir, Emtricitabine And Tenofovir Alafenamide For Treatment Of HIV

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Marketing Authorization Application (MAA) for an investigational, once-daily single tablet regimen containing bictegravir (50 mg; BIC), a novel...

Gilead Sciences To Release Second Quarter 2017 Financial Results On Wednesday, July 26, 2017

Gilead Sciences To Release Second Quarter 2017 Financial Results On Wednesday, July 26, 2017

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2017 financial results will be released on Wednesday, July 26, after the market closes.

3 Red-Hot Biotech Stocks That Could Get Even Hotter

3 Red-Hot Biotech Stocks That Could Get Even Hotter

An analyst weighs in.

This $156 Billion Hedge Fund 'Hate List' Is Dead Wrong About These Stocks

This $156 Billion Hedge Fund 'Hate List' Is Dead Wrong About These Stocks

There's reason to believe they got one wrong.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.